ANI Pharmaceuticals
Princeton, New Jersey, United States · Biotechnology, Pharmaceutical
ANI Pharmaceuticals, Inc. is a global pharmaceutical company with a strategic focus on expanding its Rare Disease business. The company aims to deliver substantial shareholder value creation through high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and substantial growth thereafter. ANI is dedicated to serving patients and improving lives through its diversified port
Key facts
- Headquarters
- Princeton, New Jersey, United States
- Employees
- 418
- Industries
- Biotechnology, Pharmaceutical
- Status
- Public (ANIP)
- Website
- anipharmaceuticals.com
- Company page
Recent activity at ANI Pharmaceuticals
- : ANI Pharmaceuticals offers to acquire Egetis
- : SEC 8-K (1.01): On November 4, 2026, ANI Pharmaceuticals, Inc. entered into a Credit Agreement for a 364-day senior bridge facility worth up to $676 million with JPMorgan Chase Bank, N.A. as the administrative agent. This facility will initially be unsecured and is intended to support the Company's public cash offer for all outstanding shares, a convertible loan, and related warrants of Egetis Therapeutics AB. The agreement includes specific terms regarding interest rates and events of default, providing a strategic avenue for ANI to refinance existing debts and support acquisitions. The funding is critical as it will also impact the financial health and operational flexibility of both ANI and Egetis.
- : SEC 8-K (5.02): On August 19, 2026, ANI Pharmaceuticals, Inc. appointed Henry Gosebruch to its Board of Directors. Mr. Gosebruch, 53, currently serves as CEO of Lakefront Biotherapeutics NV, which focuses on developing medicines for serious diseases. He has a notable background in the biotechnology field, including previous roles at Neumora Therapeutics. His term will expire at the 2027 annual meeting of stockholders, indicating a strategic move to enhance the company's governance and bring in expertise from the biotech sector.
- : SEC 8-K (7.01): On August 7, 2026, ANI Pharmaceuticals, Inc. published an updated investor presentation on their website. The presentation is intended for use in meetings with investors and analysts, indicating a strategic effort to engage stakeholders and provide updates on the company's performance and strategy. The investor presentation, which underscores the company's outreach and communication strategy, is expected to impact investor relations positively. A copy of the presentation is included as Exhibit 99.2 in the filing, highlighting the company's ongoing transparency and commitment to keeping investors informed.
- : SEC 8-K (5.02): On May 21, 2026, ANI Pharmaceuticals, Inc. held its Annual Meeting of Stockholders, during which significant corporate governance matters were addressed. The stockholders approved the Amended and Restated 2022 Stock Incentive Plan, facilitating new stock-based compensation arrangements. Additionally, seven directors were elected to serve until the 2027 Annual Meeting, and Ernst & Young LLP was ratified as the independent registered accounting firm for the fiscal year ending December 31, 2026. The stockholders also provided advisory approvals for the compensation of named executive officers, and it was decided that future advisory votes on executive compensation will occur annually. This Annual Meeting reflects crucial governance changes, impacting the management structure and incentivization of the executives of the company.
- : SEC 8-K (7.01): On May 13, 2026, ANI Pharmaceuticals, Inc. published an updated investor presentation on its website, which will be utilized in upcoming meetings with investors and analysts. This presentation is intended to provide current information regarding the company's strategies and performance. The document attached as Exhibit 99.1 includes the detailed investor presentation materials dated May 2026. Such updates are essential for maintaining transparency and fostering investor relations, especially in light of the company's ongoing projects and goals.
- : SEC 8-K (7.01): On March 3, 2026, ANI Pharmaceuticals, Inc. will participate in the Raymond James & Associates’ 47th Annual Institutional Investors Conference in Orlando, Florida, with President & CEO Nikhil Lalwani presenting alongside the executive leadership team. The company is providing an updated investor presentation for this conference which may also be utilized in future meetings with investors and analysts. This updated presentation, dated March 2026, is attached as Exhibit 99.1. The event highlights ANI Pharmaceuticals' strategic communication and engagement with stakeholders, underscoring its commitment to transparency and investor relations.
- : SEC 8-K (7.01):
- : SEC 8-K (5.02):
- : SEC 8-K (7.01):
Leadership
- Stephen Carey, Chief Financial Officer
- Nikhil Lalwani, Chief Executive Officer
Verified email and direct lines for ANI Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
ANI Pharmaceuticals in the news
- ANI Pharmaceuticals to Present at Upcoming November Investor Conferences - GlobeNewswire (Nov 03, 2026)
- ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET - GlobeNewswire (Oct 23, 2026)
- ANI Pharmaceuticals to Present at Upcoming November Investor Conferences - GlobeNewswire (Nov 03, 2026)
- ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension - GlobeNewswire (Sep 23, 2026)
- ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results - GlobeNewswire (Aug 07, 2026)
- ANI Pharmaceuticals Announces Positive Six-Month Topline - GlobeNewswire (Jul 13, 2026)
- ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance - GlobeNewswire (May 08, 2026)
Companies similar to ANI Pharmaceuticals
- Kiniksa Pharmaceuticals, Ltd. · Biotechnology, Pharmaceutical
- PCCA · Biotechnology, Pharmaceutical
- Envirotainer · Biotechnology, Pharmaceutical
- Crinetics Pharmaceuticals · Biotechnology, Pharmaceutical
- Nxera Pharma Ltd · Biotechnology, Pharmaceutical
About ANI Pharmaceuticals: questions and answers
What does ANI Pharmaceuticals do?
ANI Pharmaceuticals, Inc. is a global pharmaceutical company with a strategic focus on expanding its Rare Disease business. The company aims to deliver substantial shareholder value creation through high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and substantial growth thereafter. ANI is dedicated to serving patients and improving lives through its diversified port
Where is ANI Pharmaceuticals headquartered?
ANI Pharmaceuticals is headquartered in Princeton, New Jersey, United States.
How many employees does ANI Pharmaceuticals have?
ANI Pharmaceuticals has about 418 employees.
Who leads ANI Pharmaceuticals?
Nikhil Lalwani is a Chief Executive Officer at ANI Pharmaceuticals.
What is the latest news on ANI Pharmaceuticals?
On Nov 05, 2026, ANI Pharmaceuticals offers to acquire Egetis
Is ANI Pharmaceuticals a public company?
Yes. ANI Pharmaceuticals is publicly traded under the ticker ANIP.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy